Sugi Predict

Sugi Predict / Compounds / SCHEMBL7779146

SCHEMBL7779146

SCHEMBL7779146

O=C(CBr)c1ccc(Br)c(C(F)(F)F)c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 6/20 0.58
▸ GSK3B P49841 6/20 0.58
▸ MAPT P10636 3/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ XBP1 P17861 1/20 0.51
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ HTT P42858 2/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ LMNA P02545 2/20 0.48
▸ NOTUM Q6P988 1/20 0.45
▸ EPHX1 P07099 2/20 0.42
▸ TAS2R14 Q9NYV8 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ DDR1 Q08345 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30580694 1.00 PTPN1 (0.58) PTPN1GSK3BMAPTNPSR1XBP1
SCHEMBL9955538 0.88 NOTUM (0.59) PTPN1GSK3BMAPTNPSR1XBP1
SCHEMBL5365512 0.87 GSK3B (0.59) PTPN1GSK3BMAPTNPSR1XBP1
SCHEMBL28826568 0.84 MAPT (0.50) GSK3BMAPTNPSR1XBP1MEN1
SCHEMBL30129534 0.84 PTPN1 (0.56) PTPN1GSK3B
SCHEMBL129133 0.84 PTPN1 (0.56) PTPN1GSK3B
SCHEMBL20703102 0.83 MAPT (0.47) PTPN1GSK3BMAPTNPSR1XBP1
SCHEMBL1726226 0.83 GSK3B (0.54) PTPN1GSK3BMAPTMEN1KMT2A
SCHEMBL16140755 0.83 GSK3B (0.54) PTPN1GSK3BMAPTNPSR1XBP1
SCHEMBL7787247 0.83 GSK3B (0.54) PTPN1GSK3BMAPTNPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258323-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2025-03-25 — — US disclosed
US-20240182452-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-06-06 — — US disclosed
CN-111212647-B Dihydro oxadiazinones 拜耳股份有限公司 2024-05-14 — — CN disclosed
US-11897867-B2 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer BAYER AKTIENGESELLSCHAFT (DE) 2024-02-13 — — US disclosed
US-11773070-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2023-10-03 — — US disclosed
US-11773070-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2023-10-03 — — US disclosed
US-11773070-B2 Dihydrooxadiazinones BAYER AKTIENGESELLSCHAFT (DE) 2023-10-03 — — US disclosed
EP-3661517-B1 DIHYDROOXADIAZINONES BAYER AG (DE) 2023-09-13 — — EP disclosed
EP-3661517-B1 DIHYDROOXADIAZINONES BAYER AG (DE) 2023-09-13 — — EP disclosed
US-20230017200-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2023-01-19 — — US disclosed
EP-3661517-A1 DIHYDROOXADIAZINONES Bayer Aktiengesellschaft (DE) 2020-06-10 — — EP disclosed
CN-111212647-A Dihydroxadiazinones 拜耳股份有限公司 2020-05-29 — — CN disclosed
WO-2019025562-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2019-02-07 — — WO disclosed
WO-2019025554-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2019-02-07 — — WO disclosed
WO-2019025562-A1 DIHYDROOXADIAZINONES BAYER AKTIENGESELLSCHAFT (DE) 2019-02-07 — — WO disclosed
WO-2019025554-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2019-02-07 — — WO disclosed
US-20170253614-A1 HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) 2017-09-07 — — US disclosed
EP-0735142-B1 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICALS CO LTD (JP) 2001-10-24 — — EP disclosed
US-5717116-A TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) 1998-02-10 — — US disclosed
EP-0735142-A2 Process for producing (R)-styrene oxides SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) 1996-10-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182452-A1 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER PDE3A, PDE3B, PDE5A PTPN1 1029/4885GSK3B 1199/4885MAPT 4581/4885
US-11773070-B2 Dihydrooxadiazinones CCND2, DPYD, DHPS PTPN1 2719/4885GSK3B 2451/4885MAPT 4231/4885
US-20170253614-A1 HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS HAVCR2, HCCS, LIPC PTPN1 417/4885GSK3B 591/4885MAPT 3166/4885
US-12258323-B2 Dihydrooxadiazinones CCND2, CCNT2, CCND1 PTPN1 2650/4885GSK3B 2356/4885MAPT 4154/4885
US-20230017200-A1 DIHYDROOXADIAZINONES CCND2, CCNT2, CCND1 PTPN1 2650/4885GSK3B 2356/4885MAPT 4154/4885
US-11897867-B2 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer PDE3B, PDE3A, PDE5A PTPN1 1605/4885GSK3B 515/4885MAPT 4097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.